Comparative Pharmacology
Head-to-head clinical analysis: CERETEC versus GALLIUM CITRATE GA 67.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERETEC versus GALLIUM CITRATE GA 67.
CERETEC vs GALLIUM CITRATE GA 67
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m exametazime (Ceretec) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is taken up by brain tissue in proportion to regional cerebral blood flow. Once inside cells, it undergoes intracellular conversion to a hydrophilic form, trapping it in the brain and allowing SPECT imaging.
Gallium citrate Ga 67 is a radiopharmaceutical that localizes in tumors and inflammatory lesions. The mechanism is not fully understood but may involve binding to transferrin and uptake via transferrin receptors, as well as accumulation in lysosomes of macrophages and tumor cells.
555-740 MBq (15-20 mCi) intravenously as a single dose for SPECT imaging.
2-5 mCi (74-185 MBq) intravenously once; repeat imaging may require an additional 2-5 mCi at 48-72 hours.
None Documented
None Documented
Terminal: 6 hours (range 4–8 h); clinical: supports twice-daily dosing in nuclear medicine studies.
Terminal elimination half-life: approximately 25 days (range 6-72 days) in soft tissues; reflects slow clearance from binding sites (e.g., transferrin, lactoferrin).
Renal: 40% unchanged; biliary/fecal: 60% (as metabolites and parent compound).
Renal: approximately 25% within first 24 hours; fecal: approximately 10% within 48 hours; retained in tissues (bone, liver, spleen) with slow release over weeks.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical